Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
| العنوان: | Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues |
|---|---|
| المؤلفون: | Gaiqin Yan, Yue Li, Jun Cheng, Huichun Xing, Shibo Ji, Shunai Liu, Calvin Q. Pan |
| المصدر: | Experimental and Therapeutic Medicine |
| بيانات النشر: | D.A. Spandidos, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Hepatitis B virus, Cancer Research, medicine.medical_specialty, business.industry, outcome predictors, Salvage therapy, General Medicine, Entecavir, Articles, medicine.disease_cause, Gastroenterology, Immunology and Microbiology (miscellaneous), HBeAg, Telbivudine, Internal medicine, suboptimal response, IL-21, antiviral therapy, medicine, Adefovir, Clinical endpoint, business, Prospective cohort study, hepatitis B virus, medicine.drug |
| الوصف: | To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log10 S/CO, 5.2 (3.5-7.5) log10 IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R2=0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013). |
| اللغة: | English |
| تدمد: | 1792-1015 1792-0981 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::621fdef5f665d0b556fc2c862ec8d188Test http://europepmc.org/articles/PMC7818553Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....621fdef5f665d0b556fc2c862ec8d188 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17921015 17920981 |
|---|